Barclays raised the firm’s price target on Amneal Pharmaceuticals to $5 from $4 and keeps an Overweight rating on the shares. The shares are 22% following the Q2 “beat and raise,” with growth across complex generic and biosimilars, the analyst tells investors in a research note. The firm cites and improved outlook for the year and strong top-line growth for the target bump.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AMRX:
- Amneal Pharmaceuticals raises FY23 operating cash flow view to $220M-$250M
- Amneal Pharmaceuticals raises FY23 adjusted EPS view to 45c-55c from 40c-50c
- Amneal Pharmaceuticals reports Q2 adjusted EPS 19c, consensus 11c
- AMRX Upcoming Earnings Report: What to Expect?
- Amneal Pharmaceuticals submits ANDA to FDA for three key complex generics